Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
NOVO NORDISK A/S |
Delayed
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 647.50 DKK | -0.40% | -2.28% | +38.06% | |
| Sep. 27 | Global markets live: Costco, Amazon, Tesla, Target, Pendragon... |  |
| Sep. 27 | EU Health Agency to Assess Weight Loss Drugs' Anesthesia-related Complication Risk | MT |
| Sales 2023 * | 224 B 31,604 M | Sales 2024 * | 264 B 37,236 M | Capitalization | 2896 B 408 B |
|---|---|---|---|---|---|
| Net income 2023 * | 79,256 M 11,169 M | Net income 2024 * | 91,729 M 12,927 M | EV / Sales 2023 * | 12,8x |
| Net cash position 2023 * | 15,517 M 2,187 M | Net cash position 2024 * | 33,328 M 4,697 M | EV / Sales 2024 * | 10,8x |
| P/E ratio 2023 * | 36,5x | P/E ratio 2024 * | 31,0x | Employees | - |
| Yield 2023 * | 1,27% | Yield 2024 * | 1,49% | Free-Float | 80.61% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 day | -0.40% | ||
| 1 week | +0.08% | ||
| Current month | +1.65% | ||
| 1 month | +1.33% | ||
| 3 months | +20.47% | ||
| 6 months | +23.45% | ||
| Current year | +38.06% |
1 week
630.00
663.40
1 month
630.00690.30
Current year
448.25690.30
1 year
369.00690.30
3 years
203.45690.30
5 years
132.58690.30
10 years
89.80690.30
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 57 | 2016 | |
| Director of Finance/CFO | 52 | 2018 | |
| Chief Operating Officer | 53 | 2016 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Martin MacKay
BRD | Director/Board Member | 67 | 2018 |
Andreas Fibig
BRD | Director/Board Member | 61 | 2018 |
Helge Lund
CHM | Chairman | 61 | 2018 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 21.31% | 162 M$ | +11.96% | ||
| 6.30% | 19 M$ | +4.23% | - | |
| 5.40% | 30 M$ | +4.96% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23-09-27 | 647.50 | -0.40% | 2,086,701 |
| 23-09-26 | 650.10 | +2.02% | 3,070,633 |
| 23-09-25 | 637.20 | -0.65% | 2,109,465 |
| 23-09-22 | 641.40 | -0.14% | 2,401,391 |
| 23-09-21 | 642.30 | -3.06% | 2,711,767 |
Delayed Quote Nasdaq Copenhagen, September 27, 2023 at 10:59 am EDT
More quotes
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes treatment products (78.9%);
- rare disease treatment products (11.6%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.;
- obesity treatment products (9.5%).
Net sales are distributed geographically as follows: Europe/Middle East/Africa (25%), the United States (47.8%), North America (3.6%), China (9.2%) and other (14.4%).
Sector
Pharmaceuticals
Calendar
2023-11-02
- Q3 2023 Earnings Release
Trading Rating :
Investor Rating :
ESG Refinitiv :
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
647.50DKK
Average target price
644.48DKK
Spread / Average Target
-0.47%
EPS Revisions
| 1st Jan change | Capi. (M$) | |
|---|---|---|
| +38.06% | 412 B $ | |
| -11.06% | 383 B $ | |
| +50.27% | 495 B $ | |
| -5.25% | 272 B $ | |
| -6.32% | 267 B $ | |
| -13.25% | 220 B $ | |
| -0.89% | 210 B $ | |
| +10.61% | 210 B $ | |
| -37.35% | 183 B $ | |
| +2.41% | 144 B $ |
